BioCentury
ARTICLE | Company News

CHMP backs pair of RCC drugs

July 22, 2016 7:00 AM UTC

On Friday, EMA's CHMP recommended approval of two drugs to treat advanced renal cell carcinoma in patients previously treated with a VEGF inhibitor. The committee recommended Kisplyx lenvatinib from Eisai Co. Ltd. (Tokyo:4523) in combination with Afinitor everolimus, and Cabometyx cabozantinib from Exelixis Inc. (NASDAQ:EXEL) as a monotherapy. Ipsen Group (Euronext:IPN) holds Cabometyx's rights outside the U.S., Canada and Japan.

Kisplyx is an inhibitor of multiple VEGF receptor tyrosine kinases. Cabometyx is a tablet formulation of cabozantinib, a spectrum-selective kinase inhibitor of VEGF receptor 2 ( VEGFR-2; KDR/Flk-1) and c-Met receptor tyrosine kinase (c-MET; MET; HGRF; c-Met proto-oncogene). ...